Cystic Fibrosis Foundation issued the following clinical trial alert in October.

October 6, 2021

Study of VX-121 in people with CF ages 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation

Status: Enrolling

Description: This study will look at the safety and effectiveness of VX-121/tezacaftor/deutivacaftor, a drug combination intended to help CFTR protein function closer to normal.

Age: 12 Years and Older

Mutation: One Copy F508del

Fev1% Predicted: 40 to 90%

Number of Visits: 19

Length of Participation: 64 weeks link: